Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Infant Bacterial Therapeutics

54.8

 

SEK

 

-2.66 %

Less than 1K followers

IBT B

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus

Infant Bacterial Therapeutics is a biotechnology company focused on developing innovative treatments for inflammatory bowel diseases. The company develops, among other things, medicines to treat and prevent common conditions and diseases in children that occur at early birth. The business is global with a primary presence in Europe and North America. Infant Bacterial Therapeutics was founded in 2011 and is headquartered in Stockholm, Sweden.

Read more
Market cap
738.23M SEK
Turnover
581.31K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
20/8
2025

Interim report Q2'25

13/11
2025

Interim report Q3'25

All
Press releases
ShowingAll content types
Press release5/14/2025, 5:30 AM

Infant Bacterial Therapeutics (IBT) presenterar resultat från ”The Connection Study” vid ESPGHAN 2025 i Helsingfors

Infant Bacterial Therapeutics
Press release5/14/2025, 5:30 AM

Infant Bacterial Therapeutics (IBT) to present results of “The Connection Study” at ESPGHAN 2025 in Helsinki

Infant Bacterial Therapeutics
Regulatory press release5/8/2025, 3:45 PM

Årsstämma i Infant Bacterial Therapeutics

Infant Bacterial Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/8/2025, 3:45 PM

Annual General Meeting of Infant Bacterial Therapeutics

Infant Bacterial Therapeutics
Press release5/8/2025, 5:00 AM

IBT skickar in klinisk studierapport för “The Connection Study” till FDA

Infant Bacterial Therapeutics
Press release5/8/2025, 5:00 AM

IBT Submits Clinical Study Report for ‘The Connection Study’ to the FDA

Infant Bacterial Therapeutics
Regulatory press release5/7/2025, 12:30 PM

Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari – 31 mars 2025

Infant Bacterial Therapeutics
Regulatory press release5/7/2025, 12:30 PM

Infant Bacterial Therapeutics AB (publ) Interim report January 1 – March 31, 2025

Infant Bacterial Therapeutics
Press release4/24/2025, 5:20 AM

Infant Bacterial Therapeutics (IBT) kommer att presentera resultat från ”The Connection Study” vid PAS 2025 i Honolul

Infant Bacterial Therapeutics
Press release4/24/2025, 5:20 AM

Infant Bacterial Therapeutics (IBT) to Present Results of “The Connection Study” at PAS 2025 in Honolulu

Infant Bacterial Therapeutics
Regulatory press release4/9/2025, 2:20 AM

Finansinspektionen: Flaggningsmeddelande i Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics
Regulatory press release4/7/2025, 7:40 AM

Kallelse till årsstämma i Infant Bacterial Therapeutics

Infant Bacterial Therapeutics
Regulatory press release4/7/2025, 7:40 AM

Notice of Annual General Meeting of Infant Bacterial Therapeutics

Infant Bacterial Therapeutics
Regulatory press release3/28/2025, 5:52 PM

IBT beviljas “Breakthrough Therapy Designation” för sin läkemedelskandidat

Infant Bacterial Therapeutics
Regulatory press release3/28/2025, 5:52 PM

IBT is granted Breakthrough Therapy Designation for its Drug Candidate

Infant Bacterial Therapeutics
Regulatory press release3/27/2025, 7:00 AM

Infant Bacterial Therapeutics AB publicerar Årsredovisning för 2024

Infant Bacterial Therapeutics
Regulatory press release3/27/2025, 7:00 AM

Infant Bacterial Therapeutics AB publishes the Annual Report for 2024

Infant Bacterial Therapeutics
Regulatory press release2/13/2025, 7:30 AM

Infant Bacterial Therapeutics AB (publ) Bokslutskommuniké 1 januari – 31 december 2024

Infant Bacterial Therapeutics
Regulatory press release2/13/2025, 7:30 AM

Infant Bacterial Therapeutics AB (publ) Year-end report January 1 – December 31, 2024

Infant Bacterial Therapeutics
Press release12/20/2024, 3:33 PM

IBT fortsätter utvecklingen av läkemedelskandidaten IBP-9414

Infant Bacterial Therapeutics
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team